Compare BIO & SEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIO | SEIC |
|---|---|---|
| Founded | 1952 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Bankers/Brokers/Service |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.9B |
| IPO Year | N/A | N/A |
| Metric | BIO | SEIC |
|---|---|---|
| Price | $322.16 | $87.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $358.50 | $102.43 |
| AVG Volume (30 Days) | 169.4K | ★ 627.2K |
| Earning Date | 02-12-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | N/A | ★ 30.71 |
| EPS | N/A | ★ 5.43 |
| Revenue | ★ $2,557,500,000.00 | $2,246,646,000.00 |
| Revenue This Year | $1.62 | $9.87 |
| Revenue Next Year | $2.26 | $8.01 |
| P/E Ratio | ★ N/A | $16.13 |
| Revenue Growth | N/A | ★ 9.44 |
| 52 Week Low | $211.43 | $64.66 |
| 52 Week High | $373.69 | $93.96 |
| Indicator | BIO | SEIC |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 63.21 |
| Support Level | $300.26 | $81.63 |
| Resistance Level | $328.25 | $88.25 |
| Average True Range (ATR) | 7.13 | 1.62 |
| MACD | 2.59 | 0.35 |
| Stochastic Oscillator | 75.18 | 83.67 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.